Computational modelling and invitro evaluation identified natural product - Z218 as a novel Janus Kinase-2 (JAK2) inhibitor to combat Beta Thalassemia.
Sign Up to like & getrecommendations! Published in 2023 at "Biotechnology and applied biochemistry"
DOI: 10.1002/bab.2459
Abstract: Aberrant activity of Janus kinase 2 (JAK2) is a known driver of several myeloproliferative disorders, including polycythemia Vera, and Thalassemia. Several inhibitors have been proposed to inhibit JAK2 activity in order to control the disease… read more here.
Keywords: kinase jak2; kinase; jak2; natural product ... See more keywords
Chrysophanol attenuated isoproterenol‐induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway
Sign Up to like & getrecommendations! Published in 2019 at "Cell Biology International"
DOI: 10.1002/cbin.11146
Abstract: Cardiac hypertrophy is a common pathological change found in various cardiovascular diseases. Although it has long been recognized as an important risk factor responsible for heart failure, there is still a lack of effective treatments… read more here.
Keywords: cardiac hypertrophy; transcription; induced cardiac; hypertrophy ... See more keywords
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.31986
Abstract: Canonical Janus kinase 2 (JAK2) V617F and exon 12 mutations in myeloid neoplasms are well described. There are limited reports of other JAK2 variants of potential clinical relevance. This study was designed to survey JAK2… read more here.
Keywords: myeloproliferative neoplasms; myeloid leukemia; janus kinase; acute myeloid ... See more keywords
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Immunology"
DOI: 10.1002/eji.202149173
Abstract: Cytokine signaling, especially interferon (IFN) signaling is closely linked to several aspects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. During initial SARS‐CoV‐2 infection, symptomatic patients present with impaired type I/III IFN‐mediated antiviral responses.… read more here.
Keywords: sars cov; jak; cov infection; janus kinase ... See more keywords
Janus Kinase Inhibitors and Non-Melanoma Skin Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-020-00815-y
Abstract: JAK (janus kinase) inhibitors are becoming increasingly prescribed for various conditions from dermatologic diseases to graft versus host disease in bone marrow transplant recipients. This class of drugs has been found to be truly life-changing… read more here.
Keywords: kinase inhibitors; non melanoma; skin; skin cancer ... See more keywords
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2021 at "Infection"
DOI: 10.1007/s15010-021-01730-6
Abstract: The Coronavirus disease 2019 (COVID-19) pandemic is one of the most devastating global problems. Regarding the lack of disease-specific treatments, repurposing drug therapy is currently considered a promising therapeutic approach in pandemic situations. Recently, the… read more here.
Keywords: combination therapy; baricitinib; therapy; infection ... See more keywords
Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Sign Up to like & getrecommendations! Published in 2020 at "Drug Safety"
DOI: 10.1007/s40264-020-00938-z
Abstract: The introduction of novel, small-molecule Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics. This review aimed to… read more here.
Keywords: baricitinib; tofacitinib baricitinib; drug; baricitinib upadacitinib ... See more keywords
Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?
Sign Up to like & getrecommendations! Published in 2020 at "Current Treatment Options in Rheumatology"
DOI: 10.1007/s40674-020-00155-w
Abstract: Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease. There is a need for newer therapies to achieve disease control and reduce steroid related morbidity and mortality. Janus Kinase (JAK) inhibitors (Jakinibs) represent a new… read more here.
Keywords: sle; treatment; inhibition; lupus ... See more keywords
Janus kinase inhibitor ruxolitinib blocks thymic regeneration after acute thymus injury.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2019.113712
Abstract: Thymic epithelial cells (TECs) are crucial for the production of T-cells. Cancer therapies including cytotoxic drugs and ionizing radiations damage TECs resulting in abnormal T-cell production and function. Fortunately, TECs can regenerate after injury. The… read more here.
Keywords: ruxolitinib; thymus injury; regeneration; injury ... See more keywords
Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
Sign Up to like & getrecommendations! Published in 2017 at "Human immunology"
DOI: 10.1016/j.humimm.2016.12.005
Abstract: Inhibition of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway for immunosuppression in solid organ transplantation is appealing due to its specificity for immune cell function, particularly for JAK3. This is due to… read more here.
Keywords: immunosuppression solid; solid organ; organ transplantation; transplantation ... See more keywords
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.10.043
Abstract: To the Editor: Alopecia areata (AA) is a common autoimmune disease. Although oral Janus kinase (JAK) inhibitors have emerged as promising targeted treatment for AA, data regarding topical JAK inhibitors are lacking. Here, we describe… read more here.
Keywords: alopecia areata; pilot study; study patients; treatment ... See more keywords